Telomir Pharmaceuticals Inc. has announced promising preclinical results from its ongoing development of Telomir-1, an investigational oral small molecule candidate for treating age-related macular degeneration $(AMD)$. The study utilized the Sen57wrn-/-ND6-/+ zebrafish model, which reflects key features of dry AMD and geographic atrophy observed in humans. Over a 14-day period, Telomir-1 was administered orally to 18-month-old animals. The treatment resulted in improved central vision response and motion detection, regeneration of several critical retinal layers, and a reduction in oxidative stress. Notably, untreated animals experienced a 15% mortality rate, while no mortality was observed in the Telomir-1 treated groups. These findings are considered a significant preclinical milestone that supports the continued advancement of Telomir-1 towards an Investigational New Drug $(IND.AU)$ submission.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.